Provided is a catalyst for amide compound hydrogenation characterized in that rhodium and molybdenum are supported on hydroxyapatite, the catalyst for amide compound hydrogenation providing a catalyst that can promote a reduction reaction that converts an amide compound into an amine compound, can be used under moderate conditions, and has durability that allows repeated use thereof while retaining high activity. Also provided is a method for producing an amine compound, the method being characterized by including bringing an amide compound into contact with the catalyst for amide compound hydrogenation to cause hydrogenation, thereby producing an amine compound.

The present invention relates to a method of mono-deuterated-lower-alkylating the amine part in a compound having an amine protected with an aralkyl, which comprises introducing mono-deuterated lower-alkyl into the amine with a deuterated-lower-alkylating agent under neutral or basic condition, and then deprotecting the aralkyl group.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form of 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d.sub.5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d.sub.3)piperazine in the form of 2a and 2b, wherein X—is a counter ion, or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising prodrugs, or pharmaceutically acceptable salts thereof, of the invention. ##STR00001## ##STR00002##

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

The present invention relates to a process for the preparation of amorphous Selexipag from Selexipag crystalline salts using a solvent.

Disclosed is a polyoxometalate compound including a metal-substituted polyoxometalate. The metal-substituted polyoxometalate includes a polyoxometalate having defect sites, a substituting metal atom introduced into the defect sites, and an organic ligand. The substituting metal atom is divalent platinum or palladium. The organic ligand may be a bidentate ligand having an aliphatic heterocycle containing two nitrogen atoms coordinately bonded to the substituting metal atom. One substituting metal atom is introduced into one defect site.